Neuren Pharmaceuticals (ASX: NEU) moved a step closer to expanding the reach of its Rett syndrome treatment, with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending approval of DAYBU® (trofinetide) in the European Union.

💊 Positive EU recommendation for DAYBU®: The CHMP has adopted a positive opinion recommending European Commission marketing authorisation for DAYBU® to treat neurobehavioral symptoms of Rett syndrome in adults and children aged five years and older. If approved, it would become the first treatment for this indication in the European Union.
🌍 Commercial milestone opportunity: Under its licensing agreement with Acadia Pharmaceuticals, Neuren would receive US$35 million following the first commercial sale of DAYBU® in Europe, along with tiered royalties on net sales and potential milestone payments of up to US$170 million based on future sales thresholds.
🧠 Expanding treatment access: The European Commission is expected to make a final decision in the coming months. If authorised, the approval would cover all 27 European Union member states, as well as Iceland, Liechtenstein and Norway, expanding access to treatment for people living with Rett syndrome.

"With no approved treatment currently available in the EU, approval of DAYBU® would represent an important step forward for patients, caregivers and the wider Rett syndrome community profoundly impacted by this devastating condition." – Jon Pilcher, Neuren Pharmaceuticals CEO

Nickel Industries (ASX:NIC) has just announced two significant transactions, both strengthening its position in Indonesia`s nickel industry and increasing its exposure to the EV battery supply chain. Nickel Industries has acquired stakes in the CNE and TMI HPAL projects, securing additional Class 1 nickel production while maintaining a disciplined approach to growth. Importantly, the Sampala Project remains central to the strategy, with the resource identified as the exclusive ore supplier to both CNE and TMI. As Nickel Industries positions to become an even larger player in the battery materials market Managing Director Justin Werner joins Lel Smits from The Stock Network to discuss the rationale behind the transactions and key catalysts to watch next.

🇮🇩 Importance of recently announced deals in Indonesia
⚒️ Unlocking the value of the Sampala Project
🚀 Future catalysts and milestones

As market volatility and diversification become bigger considerations for investors, many are rethinking the traditional approach of picking individual blue chip stocks and instead turning to ETFs for broader exposure and portfolio simplicity. In this Women in ETFs ETF Education Spotlight, The Stock Network’s Lel Smits is joined by Sacha Burchgart Founder & Managing Director of Burcheart, to discuss why ETFs are gaining traction among investors, the challenges of stock picking, and how investors can think about balancing both strategies in modern portfolios.

📈 Why investors are shifting to ETFs
🎯 The challenges of stock picking
🛡️ Diversification and risk management
💙 Can blue chip stocks still outperform?
⚖️ Building a balanced portfolio

The ASX just put every listed company on notice because of a trick called “share ramping” - it’s when companies release a stream of ASX market announcements that sound exciting to lift their share price, but are light on substance.

In its first-ever supervision report, the ASX said it will target companies that repeatedly use announcements to inflate their price. This all matters because investors rely on ASX announcements to make decisions, and not every flashy headline reflects real progress.

The crackdown is designed to restore trust by ensuring market updates inform investors, rather than influence them.

#ASX #stocks #fintok #money #investing

Artificial intelligence is creating some of the world`s fastest-growing and most valuable companies, but many of the biggest opportunities remain private and inaccessible to most investors. AI Private Opportunities Trust (ASX:AIX) is listing on the ASX this Thursday after having raised over $265 million and will be focused on providing Australian investors with exposure to leading private AI companies through a market-first ASX-listed investment vehicle. Pengana Capital Group Executive Director Adam Myers speaks with The Stock Network`s Lel Smits about the growing AI investment opportunity, why investors may be structurally under-exposed to private AI, and how AIX aims to provide access to this rapidly evolving sector.

🤖 The AI opportunity on ASX
🌐 Investing across the AI ecosystem
🚀 The AIX difference

The Calmer Co. (ASX:CCO) secures Coles acceptance for its new Fiji Kava® FZZR™ product, building on its recent strong domestic retail performance, and advances plans to expand into U.S. retail channels.

🥥 Coles accepts Fiji Kava® FZZR™: Coles approves the ranging of Fiji Kava® FZZR™, an innovative kava product that can be consumed as a sparkling drink, direct-to-mouth supplement or chewable format, with distribution expected to commence in October 2026.
🛒 Strong retail footprint and category leadership: Fiji Kava® products are currently ranked No.1 and No.3 in Coles’ national Stress category; The Calmer Co. now has distribution through both Coles and Woolworths, representing approximately 67% of Australia’s grocery retail footprint.
🇺🇸 U.S. expansion gains momentum: The company estimates it holds around 10% of Amazon USA kava sales and has appointed U.S. natural products brokerage VDriven to support expansion into U.S.-based physical retail channels.

“We are extremely pleased to see Coles support the planned launch of this innovative new Fiji Kava® format as part of its latest range review. The FZZR™ technology provides consumers with a highly convenient and enjoyable way to experience kava, while also broadening the accessibility of the category through flavour innovation and portability.” - The Calmer Co. Founder & CEO Zane Yoshida

Far East Gold (ASX:FEG) is entering a pivotal period as it advances the flagship Idenburg Gold Project in Papua Province, Indonesia, while simultaneously responding to an unsolicited takeover offer from Xinye Gold. The company has advanced the Idenburg Gold Project over the past year, growing the resource, and progressing studies and permitting as it moves toward development. At the same time, the Board has unanimously recommended shareholders reject Xinye Gold`s takeover offer, arguing it does not reflect the company`s value or future growth potential. Far East Gold Managing Director & CEO Shane Menere joins Lel Smits from The Stock Network to discuss the company`s development strategy, the rationale behind the Board`s position on the takeover offer, and the key catalysts investors should be watching in the months ahead.

⛏️ Board recommendation to reject the offer
🪓 Far East Gold valuation
⚒️ Key growth catalysts ahead
🤝 Strategic interest validation
🏭 Strategic investor strategy
🚀 The long-term opportunity

Mesoblast (ASX:MSB, Nasdaq:MESO) has entered a new chapter following the launch of Ryoncil®, with quarterly revenues growing and operating cash burn declining. At the same time, Mesoblast is advancing several late-stage programs across inflammatory diseases, chronic low back pain and heart failure, while outlining what it describes as potential "blockbuster opportunities" across its pipeline. For investors the key question is now whether it can translate its scientific platform into sustainable commercial growth and execute on multiple development programs simultaneously. Mesoblast CEO and Managing Director Dr Silviu Itescu joins Lel Smits from The Stock Network to discuss the next phase of growth, upcoming milestones and the timelines investors should be watching.

🚀 Commercial execution beyond the launch
⚕️ Turning pipeline potential into outcomes
🔬 Managing expectations around catalysts